Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -35.07% is 64% below its 5-year average of -21.36%, near the low end of its 5-year range (-35.07%–-4.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.28% below its 12-month average of -32.69%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -35.07%.
RETURN ON EQUITY (ROE)
-35.07%
RETURN ON EQUITY (ROE) AVG TTM
-32.69%
RETURN ON EQUITY (ROE) AVG 3Y
-26.39%
RETURN ON EQUITY (ROE) AVG 5Y
-21.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.28%
CURRENT VS 3Y AVG
-32.88%
CURRENT VS 5Y AVG
-64.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
+8.31%
vs the sector median at left
Design Therapeutics, Inc.
Market Cap
$776.65M
Return on Equity (ROE)
-35.07%
TTM Avg
-32.69%
3Y Avg
-26.39%
5Y Avg
-21.36%
Market Cap
$769.83M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
Market Cap
$774.54M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
-52.14%
5Y Avg
-52.14%
Market Cap
$785.03M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$766.41M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
Market Cap
$791.64M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$756.15M
Return on Equity (ROE)
-70.19%
TTM Avg
-78.37%
3Y Avg
-123.45%
5Y Avg
-79.18%
Market Cap
$812.78M
Return on Equity (ROE)
12.32%
TTM Avg
19.75%
3Y Avg
23.44%
5Y Avg
27.16%
Market Cap
$737.02M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $776.65M | -35.07% | -32.69% | -26.39% | -21.36% |
| Geron Corporation (GERN)vs › | $769.83M | -31.97% | -50.13% | -87.97% | -79.93% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.54M | -40.21% | -52.14% | -52.14% | -52.14% |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | -16.56% | 0.55% | -10.56% | -13.37% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $766.41M | -22.36% | -60.32% | -42.71% | -132.49% |
| Cytek Biosciences, Inc. (CTKB)vs › | $791.64M | -25.03% | -10.49% | -5.87% | -23.97% |
| Candel Therapeutics, Inc. (CADL)vs › | $756.15M | -70.19% | -78.37% | -123.45% | -79.18% |
| InMode Ltd. (INMD)vs › | $812.78M | 12.32% | 19.75% | 23.44% | 27.16% |
| Anteris Technologies Global Corp. (AVR)vs › | $737.02M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $825.02M | -13.30% | 11.91% | 154.09% | 54.89% |
ROE
-35.1%
ROA
-32.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -35.07% |
| 2026-03-31 | -31.97% |
| 2025-12-31 | -32.84% |
| 2025-09-30 | -33.77% |
| 2025-06-30 | -29.80% |
| 2025-03-31 | -24.66% |
| 2024-12-31 | -20.48% |
| 2024-09-30 | -18.93% |
| 2024-06-30 | -19.34% |
| 2024-03-31 | -21.77% |
| 2023-12-31 | -24.08% |
| 2023-09-30 | -25.39% |
| 2023-06-30 | -25.03% |
| 2023-03-31 | -22.17% |
| 2022-12-31 | -19.34% |
| 2022-09-30 | -16.73% |
| 2022-06-30 | -14.18% |
| 2022-03-31 | -11.69% |
| 2021-12-31 | -9.30% |
| 2021-09-30 | -7.23% |
| 2021-06-30 | -4.81% |
| 2021-03-31 | -3.22% |
